Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.
Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services
MCLEAN, Va., July 22,...
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
RIYADH, Saudi Arabia, July 09, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient and a healthcare institution, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has continued to support a patient since infancy, providing 22 years of continuous care for a rare genetic blood clotting disorder, ultimately culminating in a liver transplant—the first of its kind globally for this particular condition.
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
Signed comprehensive MOU for cooperation in shipbuilding with Cochin Shipyard Limited, India, on July 4To provide ship design, equipment support, and technical collaboration —...
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1
MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...
The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy
WASHINGTON, July 2,...
HERCULES, Calif., July 2, 2025 /PRNewswire/ -- X-Therma Inc., a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in...